Latin America Schizophrenia Drugs Agents Market By Therapeutic Class ( Second Generation Anti-psychotics, Third Generation Anti-psychotics And Others) , By Treatment ( Oral And Injectable Anti-psychotics) And By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts(2018–2023)

Latin America Schizophrenia Drugs Agents Market By Therapeutic Class ( Second Generation Anti-psychotics, Third Generation Anti-psychotics And Others) , By Treatment ( Oral And Injectable Anti-psychotics) And By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts(2018–2023)

ID: 8289 | Pages: 145 | July 2018 | Region: Latin America


Latin America Schizophrenia Drugs Agents Market was worth USD 0.700 billion in 2018 and estimated to be growing at a CAGR of 2.64%, to reach USD 0.790 million by 2023. Schizophrenia is a central nervous system disorder which affects around 1% of the total global population. It is characterised by various symptoms including hallucinations and thought disorders. It could be due to genetic, environmental or chemical factors or sometimes due to a combination of them.

Increased prevalence of schizophrenia cases and increased healthcare expenditure are driving the market growth. Increased R&D projects in the healthcare segment and growing number of cases of alcohol and drug addiction are further fuelling the market growth. There has been a arise in the demand for sophisticated treatment by patients which is propelling the market growth. However, high investment costs and lack of awareness are restraining the market growth.

The market for Schizophrenia Drugs Agents is broadly categorized into therapeutic class and treatment. By therapeutic class the market is divided into second generation anti-psychotics, third generation anti-psychotics and others. Second and third generation anti-psychotics are the preferred line of treatment for schizophrenia. By treatment the market is classified into oral and injectable anti-psychotics. On the basis of geography, the market is analysed under various regions namely Argentina, Brazil, Mexico and rest of Latin America. Latin America holds a considerable share in the market.

Some of the major companies dominating the market, by their products and services include Johnson & Johnson, Sumitomo Dainippon, Eli Lilly, Bristol-Myers Squibb/ Otsuka Pharma, AstraZeneca, Alkermes, Vanda Pharma, Allergan and Pfizer.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Therapeutic class                     

                                5.1.1 Introduction           

                                5.1.2 Second generation anti-psychotics               

                                                5.1.2.1 Risperdal

                                                5.1.2.2 Invega

                                                5.1.2.3 Zyprexa

                                                5.1.2.4 Geodon

                                                5.1.2.5 Seroquel

                                                5.1.2.6 Latuda

                                                5.1.2.7 Aristada

                                                5.1.2.8 Fanapt

                                                5.1.2.9 Saphris

                                                5.1.2.10 Vraylar

                                5.1.3 Third generation anti-psychotics   

                                5.1.4 Others      

                                5.1.5  Y-o-Y Growth Analysis, By Therapeutic class            

                                5.1.6  Market Attractiveness Analysis, By Therapeutic class          

                                5.1.7  Market Share Analysis, By Therapeutic class           

                5.2 Treatment                  

                                5.2.1 Introduction           

                                5.2.2 Oral anti-psychotics             

                                5.2.3 Injectable anti-psychotics 

                                5.2.4 Y-o-Y Growth Analysis, By Treatment          

                                5.2.5 Market Attractiveness Analysis, By Treatment        

                                5.2.6 Market Share Analysis, By Treatment         

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Therapeutic class

                                                6.1.3.3 By Treatment

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Therapeutic class

                                                6.1.4.3 By Treatment

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 Therapeutic class

                                                6.1.5.3 By Treatment

                6.2 Brazil                             

                6.3 Mexico                         

                6.4 Rest of Latin America                             

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Johnson & Johnson                 

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Bristol-Myers Squibb                              

                8.3 AstraZeneca                               

                8.4 Sumitomo Dainippon                             

                8.5 Eli Lilly                           

                8.6 Alkermes                     

                8.7 Vanda Pharma                          

                8.8 Allergan                       

                8.9 Pfizer                            

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of Therapeutic Class, By Treatment along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

                                                                                                                          

TitlePriceAdd To Cart
  1. Latin America Schizophrenia Drugs Market By Therapeutic class, From 2018-2023 ( USD Billion )
  2. Latin America Second generation anti-psychotics Market By Region, From 2018-2023 ( USD Billion )
  3. Latin America Third generation anti-psychotics Market By Region, From 2018-2023 ( USD Billion )
  4. Latin America Others Market By Region, From 2018-2023 ( USD Billion )
  5. Latin America Schizophrenia Drugs Market By Treatment, From 2018-2023 ( USD Billion )
  6. Latin America Oral anti-psychotics Market By Region, From 2018-2023 ( USD Billion )
  7. Latin America Injectable anti-psychotics Market By Region, From 2018-2023 ( USD Billion )
  8. Brazil Schizophrenia Drugs Market By Therapeutic class, From 2018-2023 ( USD Billion )
  9. Brazil Schizophrenia Drugs Market By Treatment, From 2018-2023 ( USD Billion )
  10. Argentina Schizophrenia Drugs Market By Therapeutic class, From 2018-2023 ( USD Billion )
  11. Argentina Schizophrenia Drugs Market By Treatment, From 2018-2023 ( USD Billion )
  12. Mexico Schizophrenia Drugs Market By Therapeutic class, From 2018-2023 ( USD Billion )
  13. Mexico Schizophrenia Drugs Market By Treatment, From 2018-2023 ( USD Billion )
  14. Rest of Latin America Schizophrenia Drugs Market By Therapeutic class, From 2018-2023 ( USD Billion )
  15. Rest of Latin America Schizophrenia Drugs Market By Treatment, From 2018-2023 ( USD Billion )
Middle East And Africa Angina Pectoris Drugs Market By Therapeutic Class ( Beta Blockers, Calcium Antagonists, Anticoagulants, Anti-platelets And Others) And By Region - Global Industry Analysis, Size, Share, Growth...
Asia Pacific Angina Pectoris Drugs Market By Therapeutic Class (beta Blockers, Calcium Antagonists, Anticoagulants, Anti-platelets And Others) And By Region - Global Industry Analysis, Size, Share, Growth, Trends, A...
Europe Angina Pectoris Drugs Market By Therapeutic Class ( Beta Blockers, Calcium Antagonists, Anticoagulants, Anti-platelets And Others) And By Region - Global Industry Analysis, Size, Share, Growth, Trends, And Fo...
North America Angina Pectoris Drugs Market By Therapeutic Class (beta Blockers, Calcium Antagonists, Anticoagulants, Anti-platelets And Others) And By Region - Global Industry Analysis, Size, Share, Growth, Trends, ...
Angina Pectoris Drugs Market By Therapeutic Class (beta Blockers, Calcium Antagonists, Anticoagulants, Anti-platelets And Others) And By Region - Global Industry Analysis, Size, Share, Growth, Trends, And Forecasts ...
Middle East And Africa Schizophrenia Drugs Agents Market By Therapeutic Class ( Second Generation Anti-psychotics, Third Generation Anti-psychotics And Others) , By Treatment ( Oral And Injectable Anti-psychotics) A...
Latin America Schizophrenia Drugs Agents Market By Therapeutic Class ( Second Generation Anti-psychotics, Third Generation Anti-psychotics And Others) , By Treatment ( Oral And Injectable Anti-psychotics) And By Reg...
Asia Pacific Schizophrenia Drugs Agents Market By Therapeutic Class ( Second Generation Anti-psychotics, Third Generation Anti-psychotics And Others) , By Treatment ( Oral And Injectable Anti-psychotics) And By Regi...
Europe Schizophrenia Drugs Agents Market By Therapeutic Class ( Second Generation Anti-psychotics, Third Generation Anti-psychotics And Others) , By Treatment ( Oral And Injectable Anti-psychotics) And By Region - I...
North America Schizophrenia Drugs Agents Market By Therapeutic Class ( Second Generation Anti-psychotics, Third Generation Anti-psychotics And Others) , By Treatment ( Oral And Injectable Anti-psychotics) And By Reg...
Schizophrenia Drugs Agents Market By Therapeutic Class ( Second Generation Anti-psychotics, Third Generation Anti-psychotics And Others) , By Treatment ( Oral And Injectable Anti-psychotics) And By Region - Industry...
Pharmaceutical Gelatin Market By Function (stabilizers, Thickeners, Gelling Agents And Others) , By Source( Pig Skin, Bovine Hides, Bones And Others), By Application ( Hard Capsules, Soft Capsules, Microencapsulatio...

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2018 Market Data Forecast
All Rights Reserved.